CY1108480T1 - Ανταγωνιστες κιμ-1 και χρηση για την τροποποιηση του ανοσιακου συστηματος - Google Patents
Ανταγωνιστες κιμ-1 και χρηση για την τροποποιηση του ανοσιακου συστηματοςInfo
- Publication number
- CY1108480T1 CY1108480T1 CY20081101250T CY081101250T CY1108480T1 CY 1108480 T1 CY1108480 T1 CY 1108480T1 CY 20081101250 T CY20081101250 T CY 20081101250T CY 081101250 T CY081101250 T CY 081101250T CY 1108480 T1 CY1108480 T1 CY 1108480T1
- Authority
- CY
- Cyprus
- Prior art keywords
- kim
- cell
- competitors
- modify
- immune system
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
Abstract
Αποκαλύπτεται και δημοσιοποιείται ως αναφορά η χρήση ανταγωνιστών ΚΙΜ-1 για την αναστολή της σηματοδότησης μεταξύ ενός Τ κυττάρου και ενός δεύτερους κυττάρου, π.χ., ενός εμφανίζοντος-αντιγόνα κυττάρου. Η αναστολή αυτού του είδους είναι χρήσιμη για την αγωγή παθήσεων συμπεριλαμβανομένων διαφόρων αυτοάνοσων παθήσεων και της πάθησης μοσχεύματος-έναντι-ξενιστή. Επίσης αποκαλύπτεται και δημοσιοποιείται ως αναφορά η χρήση ενός ανταγωνιστή ΚΙΜ-1 για την αναστολή της έκκρισης IFN-γ μέσω λεμφοκυττάρων ή άλλων ανοσιακών κυττάρων σε ένα θηλαστικό. Η αναστολή της IFN-γ είναι χρήσιμη για την αγωγή των φλεγμονωδών παθήσεων ή διαταραχών π.χ., της φλεγμονώδους νόσου του εντέρου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43693402P | 2002-12-30 | 2002-12-30 | |
EP03800194A EP1585546B1 (en) | 2002-12-30 | 2003-12-29 | Kim-1 antagonists and use to modulate immune system |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108480T1 true CY1108480T1 (el) | 2014-04-09 |
Family
ID=32713106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101250T CY1108480T1 (el) | 2002-12-30 | 2008-11-03 | Ανταγωνιστες κιμ-1 και χρηση για την τροποποιηση του ανοσιακου συστηματος |
Country Status (16)
Country | Link |
---|---|
US (2) | US7597887B2 (el) |
EP (2) | EP1585546B1 (el) |
JP (2) | JP4689275B2 (el) |
CN (1) | CN1835769B (el) |
AT (1) | ATE403440T1 (el) |
AU (1) | AU2003299925B2 (el) |
CA (1) | CA2512138C (el) |
CY (1) | CY1108480T1 (el) |
DE (1) | DE60322744D1 (el) |
DK (1) | DK1585546T3 (el) |
ES (1) | ES2311122T3 (el) |
HK (1) | HK1084326A1 (el) |
NZ (1) | NZ541404A (el) |
PT (1) | PT1585546E (el) |
SI (1) | SI1585546T1 (el) |
WO (1) | WO2004060041A2 (el) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2257851C (en) * | 1996-05-24 | 2011-11-15 | Biogen, Inc. | Modulators of tissue regeneration |
JP4689275B2 (ja) * | 2002-12-30 | 2011-05-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Kim−1アンタゴニストおよび免疫系を調節するための使用 |
EP1685159B1 (en) | 2003-10-03 | 2012-08-01 | Brigham & Women's Hospital | Tim-3 polypeptides |
US20050197292A1 (en) * | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
KR101213894B1 (ko) | 2005-03-02 | 2012-12-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Th2 매개성 병태를 치료하기 위한 kim-1 항체 |
KR101298433B1 (ko) * | 2005-11-18 | 2013-08-20 | 니토 보세키 가부시기가이샤 | 항원을 측정하는 방법 및 여기에 사용되는 키트 |
ITFI20090005A1 (it) * | 2009-01-19 | 2010-07-20 | Alberto Chiarugi | Formulazioni farmaceutiche per indurre immunosoppressione attraverso l'inibizione del fenomeno dell'epitope spreading e loro uso. |
US20170101471A1 (en) * | 2015-10-08 | 2017-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Blockade of tim-1 for treating graft-versus-host disease |
WO2020186149A1 (en) * | 2019-03-13 | 2020-09-17 | The Brigham And Women's Hospital, Inc. | Targeting regulatory b cells and their regulators for cancer immunotherapy |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
CA1319120C (en) | 1985-04-01 | 1993-06-15 | John Henry Kenten | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
CA2081028C (en) | 1991-03-12 | 1999-12-14 | Barbara P. Wallner | Cd2 binding domain of lymphocyte function associated antigen 3 |
US5622861A (en) | 1994-08-05 | 1997-04-22 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA encoding hepatitis A virus receptor |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US6066322A (en) | 1995-03-03 | 2000-05-23 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of immune disorders |
US6165733A (en) | 1996-05-23 | 2000-12-26 | Chiron Corporation | γ II adaptin |
CA2257851C (en) | 1996-05-24 | 2011-11-15 | Biogen, Inc. | Modulators of tissue regeneration |
JP2001503271A (ja) | 1996-11-01 | 2001-03-13 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | ヒト粘膜アドレシン細胞接着分子―1(MAdCAM―1)およびそのスプライス変異体 |
JP4094066B2 (ja) * | 1996-12-06 | 2008-06-04 | バーテックス ファーマシューティカルズ インコーポレイテッド | インターロイキン−1β変換酵素のインヒビター |
KR100764256B1 (ko) * | 1998-01-23 | 2007-10-05 | 에프. 호프만-라 로슈 아게 | 인간 인터루킨-12에 대한 항체 |
CA2319129A1 (en) | 1998-01-30 | 1999-08-05 | Human Genome Sciences, Inc. | 67 human secreted proteins |
US6528514B1 (en) | 1998-03-11 | 2003-03-04 | Welfide Corporation | IgE antibody production inhibitors and autoimmune diseases inhibitors |
US6228642B1 (en) * | 1998-10-05 | 2001-05-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression |
WO2000073498A1 (en) | 1999-06-02 | 2000-12-07 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the treatment and diagnosis of immune disorders |
EP1305409B1 (en) | 2000-06-16 | 2009-03-11 | Biogen Idec MA Inc. | Renal regulatory elements and methods of use thereof |
CA2448427C (en) * | 2001-06-01 | 2013-09-24 | Biogen, Inc. | Molecules and methods for inhibiting shedding of kim-1 |
US7838220B2 (en) | 2001-06-29 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes associated with immune disease |
NZ530451A (en) * | 2001-06-29 | 2008-04-30 | Univ Leland Stanford Junior | TIM gene sequences and their use in immunological disorders and cancer |
AU2002330039A1 (en) | 2001-09-17 | 2003-04-01 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer |
WO2003042661A2 (en) | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US7687454B2 (en) | 2001-12-03 | 2010-03-30 | The University Of British Columbia | Effectors of innate immunity determination |
AU2003303082B2 (en) | 2002-01-30 | 2009-07-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
US20050014687A1 (en) * | 2002-03-19 | 2005-01-20 | Anderson David W. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
GB0215509D0 (en) | 2002-07-04 | 2002-08-14 | Novartis Ag | Marker genes |
JP4689275B2 (ja) * | 2002-12-30 | 2011-05-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Kim−1アンタゴニストおよび免疫系を調節するための使用 |
EP3000886A1 (en) | 2003-03-19 | 2016-03-30 | Amgen Fremont Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
WO2005001092A2 (en) | 2003-05-20 | 2005-01-06 | Wyeth | Compositions and methods for diagnosing and treating cancers |
TW200539890A (en) * | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
KR20070037570A (ko) * | 2004-03-24 | 2007-04-05 | 텔로스 파마슈티칼스 인코포레이티드 | 백신에 대한 면역반응을 향상시키는 보강제로서의 조성물및 이의 사용 방법 |
-
2003
- 2003-12-29 JP JP2004565717A patent/JP4689275B2/ja not_active Expired - Fee Related
- 2003-12-29 CN CN2003801100613A patent/CN1835769B/zh not_active Expired - Fee Related
- 2003-12-29 EP EP03800194A patent/EP1585546B1/en not_active Expired - Lifetime
- 2003-12-29 US US10/540,959 patent/US7597887B2/en not_active Expired - Fee Related
- 2003-12-29 DE DE60322744T patent/DE60322744D1/de not_active Expired - Lifetime
- 2003-12-29 PT PT03800194T patent/PT1585546E/pt unknown
- 2003-12-29 EP EP08104956A patent/EP2025345A1/en not_active Withdrawn
- 2003-12-29 NZ NZ541404A patent/NZ541404A/en not_active IP Right Cessation
- 2003-12-29 DK DK03800194T patent/DK1585546T3/da active
- 2003-12-29 AU AU2003299925A patent/AU2003299925B2/en not_active Ceased
- 2003-12-29 WO PCT/US2003/041294 patent/WO2004060041A2/en active Application Filing
- 2003-12-29 AT AT03800194T patent/ATE403440T1/de active
- 2003-12-29 CA CA2512138A patent/CA2512138C/en not_active Expired - Fee Related
- 2003-12-29 SI SI200331349T patent/SI1585546T1/sl unknown
- 2003-12-29 ES ES03800194T patent/ES2311122T3/es not_active Expired - Lifetime
-
2006
- 2006-04-18 HK HK06104596A patent/HK1084326A1/xx not_active IP Right Cessation
-
2008
- 2008-11-03 CY CY20081101250T patent/CY1108480T1/el unknown
-
2009
- 2009-08-26 US US12/548,366 patent/US20100080798A1/en not_active Abandoned
-
2010
- 2010-09-21 JP JP2010211426A patent/JP5368400B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ541404A (en) | 2007-05-31 |
EP1585546A4 (en) | 2006-05-10 |
HK1084326A1 (en) | 2006-07-28 |
AU2003299925A1 (en) | 2004-07-29 |
CN1835769B (zh) | 2011-06-29 |
DE60322744D1 (de) | 2008-09-18 |
US20060222648A1 (en) | 2006-10-05 |
WO2004060041A3 (en) | 2005-01-27 |
AU2003299925A2 (en) | 2004-07-29 |
ATE403440T1 (de) | 2008-08-15 |
JP5368400B2 (ja) | 2013-12-18 |
EP1585546B1 (en) | 2008-08-06 |
US7597887B2 (en) | 2009-10-06 |
JP4689275B2 (ja) | 2011-05-25 |
EP1585546A2 (en) | 2005-10-19 |
EP2025345A1 (en) | 2009-02-18 |
PT1585546E (pt) | 2008-11-14 |
JP2006512397A (ja) | 2006-04-13 |
SI1585546T1 (sl) | 2008-12-31 |
JP2010280728A (ja) | 2010-12-16 |
CA2512138C (en) | 2013-07-16 |
CA2512138A1 (en) | 2004-07-22 |
CN1835769A (zh) | 2006-09-20 |
DK1585546T3 (da) | 2008-12-08 |
WO2004060041A2 (en) | 2004-07-22 |
AU2003299925B2 (en) | 2011-10-27 |
ES2311122T3 (es) | 2009-02-01 |
US20100080798A1 (en) | 2010-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108480T1 (el) | Ανταγωνιστες κιμ-1 και χρηση για την τροποποιηση του ανοσιακου συστηματος | |
MA27888A1 (fr) | Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons | |
MA28110A1 (fr) | Antagonistes du recepteur d'acetylcholine muscarinique | |
TW200613302A (en) | Nk1 antagonists | |
NO20054959D0 (no) | Fremgangsmater for behandling av interleukin-6 relaterte sykdommer | |
TW200612934A (en) | Quaternary salt CCR2 antagonists | |
DE60324547D1 (de) | Dreidimensionaler "coform" vliesstoff | |
DK1576011T3 (da) | Inhibering af IL-17 produktion | |
MA27900A1 (fr) | Antagonistes du recepteur de l'acetylcholine muscarinique | |
FR2854074B1 (fr) | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques | |
NZ595262A (en) | Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease | |
EA200601160A1 (ru) | 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов | |
DE60234616D1 (de) | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren | |
MX2007007152A (es) | Antagonista de naurocinina-1 con anillo en puente. | |
DE60144514D1 (de) | Verwendung von il-18 inhibitoren | |
MX2007000046A (es) | Compuestos, composiciones y metodos de imidazolo relacionados para su uso. | |
BRPI0412537A (pt) | antagonista do receptor muscarìnico da acetilcolina | |
WO2001017558A3 (en) | Novel uses of mammalian ccr6 receptors and related reagents | |
BRPI0415281A (pt) | antagonistas de receptor de acetilcolina muscarìnico | |
TR200103448T2 (tr) | IL-8 reseptör antagonistleri. | |
ITMI20041954A1 (it) | "procedimento per stimare lapendenza longitudinale del piano stradale" | |
WO2001058484A3 (en) | Novel uses of mammalian ccr8 receptors and related reagents | |
DE68919280T2 (de) | Alpha-adrenergische Rezeptorantagonisten. | |
BRPI0416202A (pt) | formulações inibidoras de fosfodiesterase v | |
FR2877201B3 (fr) | Dispositif pour l'installation et/ou l'utilisation de barres, notamment pour porte-serviette |